PubMed · 2021 · 47 citations · 262 references
Open access
Life SciencesCancer BiologyMolecular BiologyEpigenomicsProteomicsTranscriptomicsCancer ProteomicsClinical ProteomicsMulti-omics Data FusionOmics IntegrationProteomics Data IntegrationTranslational ProteomicsBiomarker Discovery From Multi-omics DataBreast Cancer HistopathologyCancer Proteome ProfilingDisease-associated Multi-omics SignaturesIntegrated Multi-omics AnalysisProteogenomic BiomarkersProteomic Data AnalysisTumor Proteomics
": phenomics/cellomics, connectomics and interactomics, secretomics, matrisomics, exosomics, angiomics, chaperomics and epichaperomics, phosphoproteomics, ubiquitinomics, metalloproteomics, terminomics, degradomics and metadegradomics, adhesomics, stressomics, microbiomics, immunomics, salivaomics, materiomics and other biomics. Throughout the extremely complex neoplastic process, a Breast Cancer Cell Continuum Concept (BCCCC) has been modeled in this review as a spatio-temporal and holistic approach, as long as the breast cancer represents a complex cascade comprising successively integrated populations of heterogeneous tumor and cancer-associated cells, that reflect the carcinoma's progression from a "driving mutation" and formation of the breast primary tumor, toward the distant secondary tumors in different tissues and organs, via circulating tumor cell populations. This BCCCC is widely sustained by a Breast Cancer Proteomic Continuum Concept (BCPCC), where each phenotype of neoplastic and tumor-associated cells is characterized by a changing and adaptive proteomic profile detected in solid and liquid minimal invasive biopsies by complex proteomics approaches. Such a profile is created, beginning with the proteomic landscape of different neoplastic cell populations and cancer-associated cells, followed by subsequent analysis of protein biomarkers involved in epithelial-mesenchymal transition and intravasation, circulating tumor cell proteomics, and, finally, by protein biomarkers that highlight the extravasation and distant metastatic invasion. Proteomics technologies are producing important data in breast cancer diagnostic, prognostic, and predictive biomarkers discovery and validation, are detecting genetic aberrations at the proteome level, describing functional and regulatory pathways and emphasizing specific protein and peptide profiles in human tissues, biological fluids, cell lines and animal models. Also, proteomics can identify different breast cancer subtypes and specific protein and proteoform expression, can assess the efficacy of cancer therapies at cellular and tissular level and can even identify new therapeutic target proteins in clinical studies.
262
Prospective identification of tumorigenic breast cancer cells
Muhammad Al‐Hajj, Max S. Wicha, Adalberto Benito‐Hernández et al. · Proceedings of the National Academy of Sciences · 2003 · 10.4K citations · Full text
Medicine, Cell Biology, Oncology +11
Ki67 expression in breast cancer
Mohamed A. Elkablawy, Abdulkader M. Albasri, Rabab Mohammed et al. · Saudi Medical Journal · 2016 · 4.4K citations · Full text
Circulating Tumor Cell Clusters Are Oligoclonal Precursors of Breast Cancer Metastasis
Nicola Aceto, Aditya Bardia, David T. Miyamoto et al. · Cell · 2014 · 2.5K citations · Full text
Medicine, Cancer Biology, Oncology +12
Targeting PI3K/mTOR Signaling in Cancer
Frontiers in Oncology · 2014 · 1K citations · Full text
Medicine, Cancer Biology, Oncology +17